Advice
Relevance to NICE guidance programmes
Relevance to NICE guidance programmes
The use of the OraQuick HCV is not currently planned into any NICE guidance programme.
NICE has issued the following guidance relevant to this briefing:
-
Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection (2012) NICE public health guidance 43
-
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (2010) NICE technology appraisal guidance 200
-
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (2004) NICE technology appraisal guidance 75
-
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (2006) NICE technology appraisal guidance 106
-
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (2013) NICE technology appraisal guidance 300
-
Telaprevir for the treatment of genotype 1 chronic hepatitis C (2012) NICE technology appraisal guidance 252
-
Boceprevir for the treatment of genotype 1 chronic hepatitis C (2012) NICE technology appraisal guidance 253